Immunovia AB News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.11.20	Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares (PR Newswire)
17.11.20	Chief Executive Officer, Patrik Dahlen Buys Immunovia Shares (PR Newswire)
12.11.20	Immunovia Reports Third Quarter Interim Report January - September 2020 (PR Newswire)
12.11.20	Immunovia Reports Third Quarter Interim Report January - September 2020 (PR Newswire)
11.11.20	Nomination Committee appointed for the 2021 Annual General Meeting of Immunovia AB (Publ) (PR Newswire)
11.11.20	Nomination Committee appointed for the 2021 Annual General Meeting of Immunovia AB (Publ) (PR Newswire)
06.11.20	Invitation to Presentation of Immunovia´s Interim Report January - September 2020 on November 12, 2020 (PR Newswire)
06.11.20	Invitation to Presentation of Immunovia´s Interim Report January - September 2020 on November 12, 2020 (PR Newswire)
02.11.20	Immunovia Provides Complementary Details on the IMMray™ PanCan-d Verification Study (PR Newswire)
02.11.20	Immunovia Provides Complementary Details on the IMMray™ PanCan-d Verification Study (PR Newswire)
30.10.20	Change in the Number of Shares and Votes in Immunovia AB (publ) (PR Newswire)
30.10.20	Change in the Number of Shares and Votes in Immunovia AB (publ) (PR Newswire)
28.10.20	Immunovia to Host Webinar Introducing New CEO, Patrik Dahlen (PR Newswire)
28.10.20	Immunovia to Host Webinar Introducing New CEO, Patrik Dahlen (PR Newswire)
27.10.20	Immunovia Provides Complementary Information on the IMMray™ PanCan-d Verification and Validation Studies (PR Newswire)
27.10.20	Immunovia Provides Complementary Information on the IMMray™ PanCan-d Verification and Validation Studies (PR Newswire)
26.10.20	Immunovia Announces Completion of Analysis from the IMMray™ PanCan-d Verification Study (PR Newswire)
26.10.20	Immunovia Announces Completion of Analysis from the IMMray™ PanCan-d Verification Study (PR Newswire)
29.09.20	Immunovia Announces Positive Results from the IMMray™ PanCan-d Verification Study (PR Newswire)
29.09.20	Immunovia Announces Positive Results from the IMMray™ PanCan-d Verification Study (PR Newswire)
23.09.20	Summary from The Extraordinary General Meeting of Immunovia (PR Newswire)
23.09.20	Summary from The Extraordinary General Meeting of Immunovia (PR Newswire)
02.09.20	Immunovia Announces Management Team Changes (PR Newswire)
02.09.20	Immunovia Announces Management Team Changes (PR Newswire)
31.08.20	Notice of Extraordinary General Meeting in Immunovia AB (PR Newswire)
31.08.20	Notice of Extraordinary General Meeting in Immunovia AB (PR Newswire)
28.08.20	Registration Details for Immunovia's Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities (PR Newswire)
28.08.20	Registration Details for Immunovia's Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities (PR Newswire)
26.08.20	Immunovia Announces CEO Transition: Appoints Patrik Dahlen as New CEO (PR Newswire)
26.08.20	Immunovia Announces CEO Transition: Appoints Patrik Dahlen as New CEO (PR Newswire)
20.08.20	Immunovia Reports Second Quarter Interim Report January - June 2020 (PR Newswire)
20.08.20	Immunovia Reports Second Quarter Interim Report January - June 2020 (PR Newswire)
18.08.20	Immunovia to Host a Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities (PR Newswire)
18.08.20	Immunovia to Host a Second Webinar in the Series on IMMray™ PanCan-d: Commercial Test Model Study & Update on Launch Activities (PR Newswire)
13.08.20	Invitation to presentation of Immunovia's interim report January - June 2020 on August 20, 2020 (PR Newswire)
13.08.20	Invitation to presentation of Immunovia's interim report January - June 2020 on August 20, 2020 (PR Newswire)
30.06.20	Change in the Number of Shares and Votes in Immunovia AB (publ) (PR Newswire)
30.06.20	Change in the Number of Shares and Votes in Immunovia AB (publ) (PR Newswire)
30.06.20	Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d (PR Newswire)
30.06.20	Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d (PR Newswire)
29.06.20	Immunovia to Present a Satellite Symposium at the European Pancreatic Club (EPC) - International Association of Pancreatology's (IAP) Annual Meeting July 2, 2020 (PR Newswire)
29.06.20	Immunovia to Present a Satellite Symposium at the European Pancreatic Club (EPC) - International Association of Pancreatology's (IAP) Annual Meeting July 2, 2020 (PR Newswire)
26.06.20	Registration Details for Immunovia's Virtual Investor Day on Tuesday, June 30, 2020 (PR Newswire)
26.06.20	Registration Details for Immunovia's Virtual Investor Day on Tuesday, June 30, 2020 (PR Newswire)
26.06.20	Immunovia Expands its Lung Cancer Program Based on Encouraging Results From the Current Discovery Study (PR Newswire)
26.06.20	Immunovia Expands its Lung Cancer Program Based on Encouraging Results From the Current Discovery Study (PR Newswire)
15.06.20	Immunovia to Host Virtual Investor Day on Tuesday, June 30, 2020 (PR Newswire)
15.06.20	Immunovia to Host Virtual Investor Day on Tuesday, June 30, 2020 (PR Newswire)
09.06.20	Immunovia Raised ~ 400m SEK to Further Accelerate the Market Introduction of the First Test for Early Detection of Pancreatic Cancer, the IMMray™ PanCan-d (PR Newswire)
04.06.20	Immunovia has Completed a Directed Share Issue and Thereby Raises Approximately MSEK 400 (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Immunovia AB

Aktien Top/Flop

Meistgelesene Nachrichten